Simbrunner, Benedikt
Caparrós, Esther
Neuwirth, Teresa
Schwabl, Philipp
Königshofer, Philipp
Bauer, David
Marculescu, Rodrig
Trauner, Michael
Scheiner, Bernhard
Stary, Georg
Mandorfer, Mattias
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Francés, Rubén
Clinical trials referenced in this document:
Documents that mention this clinical trial
Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
https://doi.org/10.1007/s12072-020-10112-3
Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
https://doi.org/10.1007/s12072-023-10496-y
FXR-FGF19 signaling in the gut–liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence
https://doi.org/10.1007/s12072-023-10636-4
Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
https://doi.org/10.1007/s12072-023-10577-y
Funding for this research was provided by:
Spanish National Plan for Scientific and Technical Research and Innovation (PID2019-107036RB-I00)
Generalitat Valenciana (PROMETEO 2021/0033)
Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development, the Christian Doppler Research Association, and Boehringer Ingelheim (Christian Doppler Laboratory for Portal Hypertension, Liver Fibrosis)
Medical University of Vienna
Article History
Received: 8 October 2022
Accepted: 4 February 2023
First Online: 7 March 2023
Declarations
:
: BeSi has received travel support from AbbVie and Gilead. DB has received travel support from AbbVie and Gilead, as well as speaker fees from AbbVie. PS received speaking honoraria from Bristol-Myers Squibb and Boehringer-Ingelheim, consulting fees from PharmaIN, and travel support from Falk and Phenex Pharmaceuticals.MP is an investigator for Bayer, BMS, Lilly, and Roche; he received speaker honoraria from Bayer, BMS, Eisai, Lilly, and MSD; he is a consultant for Bayer, BMS, Ipsen, Eisai, Lilly, MSD, and Roche; he received travel support from Bayer and BMS. MT received grant support from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda and Ultragenyx, honoraria for consulting from Abbvie, Albireo, BiomX, Boehringer Ingelheim, Falk, Genfit, Gilead, Hightide, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus and Shire, speaker fees from BMS, Falk, Gilead, Intercept MSD and Roche, as well as travel support from Abbvie, Falk, Gilead, Intercept, Jannsen and Rochet. MM served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Gilead, Collective Acumen, and W. L. Gore & Associates and received travel support from AbbVie, Bristol-Myers Squibb, and Gilead. TR received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Abbvie, Boehringer-Ingelheim, Gilead and Roche.RF received grant support from Abbvie and Janssen and served as a speaker and/or consultant and/or advisory board member for AbbVie, Janssen, Takeda, Novartis, Adacyte and GSK. EC, RM, TN, and GS declare no conflict of interest.